Skip to main content
NewslettersWatchlist

Atea Pharmaceuticals Inc(AVIR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.64
Day High3.76
Open:3.72
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Markets Today: Stocks Mixed After Hawkish ECB Comments
Motley Fool
Atea Pharmaceuticals, Inc. (AVIR) Q2 2022 Earnings Call Transcript
Globe Newswire
Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Globe Newswire
Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022
Globe Newswire
Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference
TipRanks
Atea Pharmaceuticals: Share Price Unlikely to Reflect Growth Potential
Globe Newswire
Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
Motley Fool
Atea Pharmaceuticals, Inc. (AVIR) Q1 2022 Earnings Call Transcript
Globe Newswire
Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Globe Newswire
Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting
Motley Fool
Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcript
Globe Newswire
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Globe Newswire
Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) Investigation
Globe Newswire
Atea Pharmaceuticals Highlights Strategic Priorities for 2022
Globe Newswire
Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
Globe Newswire
Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index
Globe Newswire
Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19
Globe Newswire
Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
Globe Newswire
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results
Globe Newswire
Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021
Globe NewsWire
Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference
Globe NewsWire
Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Globe NewsWire
Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses
Globe NewsWire
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results
Globe NewsWire
Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021
Globe NewsWire
Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference
Globe NewsWire
Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis
Globe NewsWire
Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche
Globe NewsWire
Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs
Globe NewsWire
Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
Globe NewsWire
Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors

Profile

Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.